Fig. 9
From: Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody
a Capillary depletion displayed as % of injected radioactivity (%ID) in parenchymal or capillary enriched fractions b [125I]mAb3D6-scFv8D3-distribution between parenchymal and capillary-enriched fraction (%) for different age and dose groups c parenchymal distribution (%) of [125I]mAb3D6-scFv8D3, pooled by dose group. Significant differences were tested with one-way analysis of variance with Bonferroni correction for multiple comparisons. For capillary depletion: young, high n = 4, young low n = 7, aged high n = 6, aged low n = 7, young 10 mg/kg n = 5, all [125I]mAb3D6 n = 13. d Representative images of nuclear track emulsion (NTE), with [125I]mAb3D6-scFv8D3 shown as white puncta, and vascular marker CD31 in red. Scale bar = 20 µm. e Quantification of percentage in parenchymal or capillary ROIs, n = 4 for all groups. f Representative western blot of TfR1 levels in capillary-enriched brain pellets from young and aged WT mice and quantification relative to loading control protein (β-actin). Whole membrane can be found in Fig.S8 (Additional file 1). Statistical analysis by unpaired t-test. Significant p-value is defined as p < 0.05, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001). g, h Nuclear track emulsion with flourecent stainings of vasculature (CD31-red) and Aβ40 (green) of [125I]mAb3D6-scFv8D3-injected or [125I]mAb3D6-injected aged tg-ArcSwe mice. Scale bar = 50 µm